[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619820":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":28,"centralContacts":28,"locations":32,"responsibleParty":43,"collaborators":28,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":28,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":28,"enrollmentInfo":55,"targetDuration":28,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":28,"overallStatus":64,"whyStopped":28,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Daewon Pharmaceutical Co., Ltd.","INDUSTRY",[8,13,16,19],{"label":9,"type":10,"description":9,"interventionNames":11},"Group1","EXPERIMENTAL",[12],"Drug: DW5524",{"label":14,"type":10,"description":14,"interventionNames":15},"Group2",[12],{"label":17,"type":10,"description":17,"interventionNames":18},"Group3",[12],{"label":20,"type":10,"description":20,"interventionNames":21},"Group4",[22],"Drug: DW5524-A",[24,29],{"type":25,"name":26,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","DW5524",[9,14,17],null,{"type":25,"name":30,"description":30,"armGroupLabels":31,"otherNames":28},"DW5524-A",[20],[33],{"facility":34,"status":28,"city":35,"state":28,"zip":28,"country":36,"countryCode":28,"cosmosGeoPoint":37,"geoPoint":42,"contacts":28},"Chungbuk National University Hospital","Cheongju-si","South Korea",{"type":38,"coordinates":39},"Point",[40,41],127.48972,36.63722,{"lat":41,"lon":40},{"type":44,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100619820","phase-1-evaluate-the-safety-tolerability-and-pharmacokinetics-of-dw5524-in-healthy-adult-volunteers-100619820",false,"NCT07349589","Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers","A Randomized, Open-label, Single-dose, Parallel-design, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged 19 years or older at the time of screening\n* Individuals weighing 50.0 kg or more and having a body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening\n\nExclusion Criteria:\n\n* Those with a current or past medical history of clinically significant liver, kidney, nervous, mental, respiratory, endocrine, blood disease, tumor, genitourinary, cardiovascular, digestive, or musculoskeletal diseases.",true,"ALL","19 Years",{"count":56,"type":57},48,"ESTIMATED","INTERVENTIONAL",[60],"PHASE1","This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5524 in healthy adult volunteers.",[63],"Healthy Adult","NOT_YET_RECRUITING","2026-01-14",{"date":67,"type":68},"2026-01-20","ACTUAL",{"date":70,"type":57},"2026-02-01",{"date":72,"type":57},"2026-12-01",{"name":5,"class":6},1]